Lawrence Eichenfield, M.D.

Bio

Dr. Eichenfield is chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics and vice-chair of the department of dermatology at UC San Diego School of Medicine. He is board certified in dermatology, pediatric dermatology and pediatrics.

After earning his medical degree from Mount Sinai School of Medicine in New York, Dr. Eichenfield was a pediatric resident and chief resident at Children's Hospital of Philadelphia. He then completed his dermatology residency at the Hospital of the University of Pennsylvania.

Along with longstanding expertise in atopic dermatitis, acne, psoriasis and other inflammatory skin conditions, Dr. Eichenfield has interests in neonatal dermatology, vascular lesions, laser surgery and rare skin disorders. He has authored more than 400 journal articles, chapters, abstracts and books, and has served as the senior editor of "Neonatal and Infant Dermatology," published by Elsevier, as well as "The Eczemas." He served as editor-in-chief of Pediatric Dermatology for 12 years and currently serves on the editorial boards of multiple journals and periodicals.

Dr. Eichenfield has held multiple leadership positions, including co-founder and co-chair of the Pediatric Dermatology Research Alliance, co-chair of the American Academy of Dermatology Guidelines for Atopic Dermatitis, co-chair of the American Acne and Rosacea Society/American Academy of Pediatrics Pediatric Acne Recommendations for Diagnosis and Treatment, member of the Expert Panel Member of the NIAID Guidelines for Diagnosis and Management of Food Allergy, Scientific Advisory Board of the National Eczema Association, and director of the Rady Children's/UC San Diego Eczema and Inflammatory Skin Disease Center. Additionally, he has served in leadership roles on guidelines and consensus statements for multiple dermatological conditions, including acne, rosacea, atopic dermatitis and psoriasis.

Dr. Eichenfield enjoys running, reading, and skiing.

Publications

Skin pain in pediatric atopic dermatitis: mechanisms and management.
Simonetti G, Mori F, Tronconi G, Oranges T, Nassini R, Eichenfield LF, Giovannini M, De Logu F

Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).
Eichenfield LF, Gonzalez ME, Boguniewicz M, Funk T, Hebert AA, Prajapati VH, Kindred C, Serrao R, Swanson L, Krupa D, Snyder S, Seal MS, Hanna D, Burnett P, Berk DR

Unilateral Parotitis in Pediatric Patients With RIME: A Report of Two Cases.
Gochnauer H, Han A, Carvalho D, Schairer D, Eichenfield LF

The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial.
Silverberg JI, Eichenfield LF, Armstrong AW, Bagel J, Lockshin B, Boh E, Koo J, Farberg AS, Goldberg MS, Quick AP, Lebwohl MG

Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies.
Blauvelt A, Kircik L, Simpson EL, Lio P, Eichenfield LF, Prajapati VH, Grewal P, Lynde C, Hong HC, Sturm D, Kallender H, Ren H, Paranagama D, Wong GKW, Geng B

Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.
Silverberg JI, Cohen D, Guttman-Yassky E, Eichenfield LF, Simpson EL, Armstrong A, Yu J, Stein-Gold L, Ehst BD, Begolka WS, Bunick CG, Chovatiya R

Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial.
Langley RG, Arkin L, Fiorillo L, Eichenfield LF, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller AS

Efficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and Sex.
Libecco J, Eichenfield LF, Hebert AA, Gold LS, Cartwright M, Moro L, Sane S, Lionnet L, Shukla D, Mazzetti A, Squittieri N, Kyeremateng K

Improving the Quality of Atopic Dermatitis Epidemiologic Research in the United States: A Systematic Review of Disease Definitions and Related Content in National Surveys.
Becker SL, Bash GN, Begolka WS, Wallace-Hood T, Takeshita J, Drucker AM, Silverberg J, Eichenfield LF, Abuabara K, Dosono B, Hamilton A, Okereke R, Simpson E

Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Simpson EL, Eichenfield LF, Papp KA, Forman SB, Hebert AA, Gonzalez ME, Gooderham MJ, Hong HC, Prajapati VH, Guttman-Yassky E, Silverberg JI, Seal MS, Krupa D, Almaraz E, Hanna D, Burnett P, Snyder S, Chu DH, Higham RC, Berk DR

Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by Age.
Kircik LH, Harper JC, Baldwin H, Eichenfield LF, Tanghetti EA, Graber E, Woolery-Lloyd HC, Guenin E, Draelos ZD

Pediatric psoriasis-associated comorbidities: beyond metabolic syndrome.
Buethe MG, Choi M, Natsis N, Eichenfield LF

Is colloidal oat an effective emollient ingredient for the prevention and treatment of atopic dermatitis in infants?
Fowler JF, Ma L, Bergman J, Horowitz P, Lavender T, Eichenfield LF, Draelos Z, Danby SG, Cork MJ

Periorificial dermatitis: Pathophysiology, diagnosis, and management.
Acevedo-Fontanez LA, Sánchez-Feliciano A, Ershadi S, Reichenberg J, Eichenfield LF, Barbieri JS

Focused update: Guidelines of care for the management of atopic dermatitis in adults.
Davis DMR, Frazer-Green L, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R

Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.
Bissonnette R, Stein Gold L, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.
Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Wine Lee L, Devani AR, Forman SB, Siri DD, Kallender H, Angel B, Li Q, Chen X, Paller AS

Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis.
Paller AS, Eichenfield LF, Irvine AD, Flohr C, Wollenberg A, Barbarot S, Bangert C, Spergel JM, Selfridge A, Biswas P, Fan H, Alderfer J, Watkins M, Koppensteiner H

Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis.
Simpson EL, Silverberg JI, Bissonnette R, Stein Gold L, Armstrong A, Hebert AA, Serrao RT, Jakus JR, Brown PM, Rubenstein DS, Piscitelli SC, Tallman AM, Eichenfield LF

Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS).
Silverberg JI, Eichenfield LF, Blauvelt A, Irvine AD, Guttman-Yassky E, Langley RG, Warren RB, French LE, Felding J, Weiss A, Pedersen CB, Jensen ML, Carlsson A, Sommer MOA, Kjøller K, Simpson EL

Patient-Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate-To-Severe Disease: Results of a Real-World, Cross-Sectional Survey.
Eichenfield LF, Shi VY, Yu J, Pierce EJ, Atwater AR, Austin J, Anderson P, Paller AS

Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry.
Eichenfield DZ, Knapp KD, Claxton A, Munoz B, Crawford JM, Balu S, Kim Y, Schneider S, Haft MA, Silverberg JI, Thaci D, Eichenfield LF, Bagel J, Rhoads JW, Paller AS, TARGET-DERM AD Investigators

Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa.
Pathmarajah P, Eid E, Nazaroff J, So J, Mittal V, Harris N, Li S, Lucky AW, Gorell ES, Peoples KG, Pope E, Lara-Corrales I, Paller AS, Wiss K, Perman MJ, Eichenfield LF, Levy ML, Morel KD, García-Romero MT, McCuaig CC, Saber M, Marinkovich MP, Oro A, Bruckner AL, Tang JY

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.
Eichenfield LF, Serrao R, Prajapati VH, Browning JC, Swanson L, Funk T, Gonzalez ME, Hebert AA, Lee M, Boguniewicz M, Simpson EL, Seal MS, Krupa D, Hanna D, Snyder S, Burnett P, Chu DH, Almaraz E, Higham RC, Berk DR

Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study.
Paller AS, Ramien M, Cork MJ, Simpson EL, Wine Lee L, Eichenfield LF, Khokhar FA, Coleman A, Gherardi G, Chen Z, Zhang A, Cyr SL

See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.

PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.